(Q34726639)

4 August 2017

1 reference

title

Ifosfamide clinical pharmacokinetics (English)

1 reference

4 August 2017

1 reference

Wagner T

1

1 reference

4 August 2017

1 June 1994

1 reference

Clinical Pharmacokinetics

4 August 2017

1 reference

4 August 2017

26

1 reference

4 August 2017

439-456

1 reference

4 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199426060-00003

4 August 2017

0 references

cites work

Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.

1 reference

12 December 2020

Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys

1 reference

12 December 2020

Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer

1 reference

12 December 2020

Enzyme stimulation and inhibition in the metabolism of drugs

1 reference

12 December 2020

Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite

1 reference

12 December 2020

Genetic variation in the human hepatic cytochrome P-450 system

1 reference

12 December 2020

Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds

1 reference

12 December 2020

Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites

1 reference

12 December 2020

Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results

1 reference

12 December 2020

Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide

1 reference

12 December 2020

Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography

1 reference

12 December 2020

Pharmacokinetics and bioavailability of oral ifosfamide

1 reference

12 December 2020

Ifosfamide in experimental tumor systems

1 reference

12 December 2020

Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds

1 reference

12 December 2020

Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism

1 reference

12 December 2020

Decreased plasma half-life of cyclophosphamide during repeated high-dose administration

1 reference

12 December 2020

Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation

1 reference

12 December 2020

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds

1 reference

12 December 2020

Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations

1 reference

12 December 2020

A simple quantitative HPLC assay for ifosfamide in biological fluids

1 reference

12 December 2020

On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)

1 reference

12 December 2020

Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells

1 reference

12 December 2020

Dechloroethylation of ifosfamide and neurotoxicity

1 reference

12 December 2020

Gas chromatographic determination of ifosfamide in microvolumes of urine and plasma

1 reference

12 December 2020

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

1 reference

12 December 2020

Irreversible encephalopathy with ifosfamide/mesna

1 reference

12 December 2020

Depletion of circulating cyst(e)ine by oral and intravenous mesna

1 reference

12 December 2020

Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.

1 reference

12 December 2020

Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy

1 reference

12 December 2020

Isolation and characterisation of two main metabolites of ifosfamide from human urine (author's transl)

1 reference

12 December 2020

Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation

1 reference

12 December 2020

Pharmacokinetics of divided‐dose ifosfamide

1 reference

12 December 2020

Ifosfamide encephalopathy: a reappraisal

1 reference

12 December 2020

Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution

1 reference

12 December 2020

Influence of buthionine sulfoximine on the lethality of ifosfamide and ifosfamide-induced urotoxicity in mice

1 reference

12 December 2020

Protection against the toxicity of alkylating agents by thiols: The mechanism of protection and its relevance to cancer chemotherapy

1 reference

12 December 2020

Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives

1 reference

12 December 2020

Mesna and oxazaphosphorine cancer chemotherapy

1 reference

12 December 2020

Fluorometric determination of acrolein and related compounds with m-aminophenol

1 reference

12 December 2020

The comparative pharmacology of cyclophosphamide and ifosfamide

1 reference

12 December 2020

Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma

1 reference

12 December 2020

Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing

1 reference

12 December 2020

Rapid gas chromatographic determination of ifosfamide in biological fluids

1 reference

12 December 2020

Phenobarbital effects on cyclophosphamide pharmacokinetics in man

1 reference

12 December 2020

Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl)

1 reference

12 December 2020

High-dose ifosfamide with mesna uroprotection: a phase I study

1 reference

12 December 2020

Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients

1 reference

12 December 2020

Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients

1 reference

12 December 2020

Ifosfamide--pharmacology, safety and therapeutic potential

1 reference

12 December 2020

Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity

1 reference

12 December 2020

Metabolism and pharmacokinetics of oral and intravenous ifosfamide

1 reference

12 December 2020

Ifosfamide neurotoxicity in children

1 reference

12 December 2020

The oxazaphosphorines

1 reference

12 December 2020

Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide

1 reference

12 December 2020

Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols

1 reference

12 December 2020

Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide

1 reference

12 December 2020

PLasma half-life and urinary excretion of cyclophosphamide in children

1 reference

12 December 2020

Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna

1 reference

12 December 2020

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna)

1 reference

12 December 2020

Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor

1 reference

12 December 2020

The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo

1 reference

12 December 2020

Increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards

1 reference

12 December 2020

Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle

1 reference

12 December 2020

Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites

1 reference

12 December 2020

Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment

1 reference

12 December 2020

Pharmacokinetic studies in lung cancer patients

1 reference

12 December 2020

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

12 December 2020

The effect of route of administration and fractionation of dose on the metabolism of ifosfamide

1 reference

12 December 2020

Bioavailability of ifosfamide in patients with bronchial carcinoma

1 reference

12 December 2020

Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects

1 reference

12 December 2020

Quantification by gas chromatography of N,N'-di-(2-chloroethyl)-phosphorodiamidic acid in the plasma of patients receiving isophosphamide

1 reference

12 December 2020

[Intracavitary chemotherapy of S 180 ascites sarcoma in mice with 4-(S-ethanol)-sulfido-cyclophosphamide in combination with protector thiols]

1 reference

12 December 2020

Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557)

1 reference

12 December 2020

The development of mesna for regional detoxification

1 reference

12 December 2020

Comparison of nitrogen-mustard-sensitive and -resistant yoshida sarcomas

1 reference

12 December 2020

Cyclophosphamide cystitis—Identification of acrolein as the causative agent

1 reference

12 December 2020

Metabolism of cyclophosphamide

1 reference

12 December 2020

Clinical pharmacology of cyclophosphamide

1 reference

12 December 2020

1 reference

12 December 2020

The fate of [14C]-mesna in the rat.

1 reference

12 December 2020

Oral bioavailability of mesna tablets

1 reference

12 December 2020

Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy

1 reference

12 December 2020

Enzymatic toxicogenation of ?Activated? cyclophosphamide by 3??5? exonucleases

1 reference

12 December 2020

Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide

1 reference

12 December 2020

Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma

1 reference

12 December 2020

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

12 December 2020

Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat

1 reference

12 December 2020

Studies on the human pharmacokinetics of isophosphamide (NSC-109724)

1 reference

12 December 2020

A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro

1 reference

12 December 2020

CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas

1 reference

12 December 2020

Ifosfamide, mesna, and nephrotoxicity in children

1 reference

12 December 2020

Bioavailability of cyclophosphamide from oral formulations

1 reference

12 December 2020

Erythrocyte glutathione and tumour response to chemotherapy

1 reference

12 December 2020

Fanconi syndrome after ifosfamide

1 reference

12 December 2020

A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC).

1 reference

12 December 2020

Prophylaxis of ifosfamide toxicity with oral acetylcysteine

1 reference

12 December 2020

Ifosfamide in refractory male germ cell tumors

1 reference

12 December 2020

Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma

1 reference

12 December 2020

A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy

1 reference

12 December 2020

Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols

1 reference

12 December 2020

Hypophosphataemic rickets after ifosfamide treatment in children

1 reference

12 December 2020

Potentiation of ifosfamide toxicity by chlordiazepoxide, diazepam and oxazepam.

1 reference

12 December 2020

Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors

1 reference

12 December 2020

Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography

1 reference

12 December 2020

Fluorometric determination of 4-hydroxyifosfamide in blood and urine

1 reference

12 December 2020

Electron-capture--gas chromatographic analysis of ifosfamide in human plasma and urine

1 reference

12 December 2020

Cyclophosphamide toxicity. Characterising and avoiding the problem

1 reference

12 December 2020

Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children

1 reference

12 December 2020

Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test

1 reference

12 December 2020

Studies on the metabolism of isopnosphamide (NSC-109724) in man

1 reference

12 December 2020

The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump

1 reference

12 December 2020

[Chemotherapy in advanced sarcomas (author's transl)]

1 reference

12 December 2020

Tubular nephrotoxicity during long-term ifosfamide and mesna therapy

1 reference

12 December 2020

Reduction of toxicity of nitrogen mustards by cysteine

1 reference

12 December 2020

2-Mercaptoethanesulfonate-cysteine disulfide excretion following the administration of 2-mercaptoethanesulfonate--a pitfall in the diagnosis of sulfite oxidase deficiency

1 reference

12 December 2020

Intracavitary chemotherapy with activated cyclophosphamides and simultaneous systemic detoxification with protector thiols in Sarcoma 180 ascites tumor

1 reference

12 December 2020

Pharmacokinetics of Cyclophosphamide in Renal Failure

1 reference

12 December 2020

Ifosfamide pharmacokinetics and neurotoxicity

1 reference

12 December 2020

Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry.

1 reference

12 December 2020

Nephrotoxicity of ifosfamide in children

1 reference

12 December 2020

The effect of age on the pharmacokinetics of ifosfamide

1 reference

12 December 2020

Rapid method for the determination of ifosfamide and cyclophosphamide in plasma by high-performance liquid chromatography with solid-phase extraction

1 reference

12 December 2020

Studies on the toxicity of cyclophosphamide in combination with mesna in vitro and in vivo

1 reference

12 December 2020

Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy

1 reference

12 December 2020

Decreased half life of cyclophosphamide in patients under continual treatment

1 reference

12 December 2020

10.2165/00003088-199426060-00003

Identifiers

DOI

1 reference

PubMed ID

8070218

Dimensions Publication ID

4 August 2017

0 references

1 reference

PubMed ID

8070218